BMGLHealthcare · Medical Care FacilitiesBMGL Stock Forecast: Basel Medical Group Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 14 Oct 2026 — in the weakest quartile.
BMGL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Basel Medical Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BMGL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMGL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMGL appears on the weeks it earns a place.
BMGL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Basel Medical Group Ltd. (BMGL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 115.0×
- Price / sales
- 0.4×
- Price / book
- 1.2×
- EV / EBITDA
- −1.9×
Cheaper than 6% of US stocks
Cheaper than 84% of US stocks
Cheaper than 63% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- 67.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −32.8%
- Net margin
- −68.2%
Higher than 89% of US stocks
Higher than 19% of US stocks
Higher than 8% of US stocks
- Return on equity
- −147.4%
- Return on assets
- −15.5%
- Dividend yield
- 0.0%
Higher than 10% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Basel Medical Group Ltd. (BMGL) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Basel Medical Group Ltd. has a market value of $6.1M and an enterprise value of $6.0M.
Trailing P/E: 115.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Basel Medical Group Ltd. employs 82 people.
Data provided by Twelve Data
BMGL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Basel Medical Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BMGL stock
How does Ticker Nerd's model rank BMGL?
As at 14 Oct 2026, Basel Medical Group Ltd. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
What is the BMGL stock forecast for 2030?
No analyst covering Basel Medical Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMGL are extrapolating price history, which says nothing about the business.
What does Basel Medical Group Ltd. do?
Basel Medical Group Ltd is a Singapore-based healthcare services provider focused on specialist medical care across orthopedics, trauma, sports medicine, neurosurgery, and general practice. The company delivers consultations, medical diagnosis, and both surgical and non-surgical treatments, with services that include joint replacement, spine care, foot and ankle procedures, minimally invasive orthopedic care, physiotherapy, and rehabilitation.
About Basel Medical Group Ltd.
Basel Medical Group Ltd is a Singapore-based healthcare services provider focused on specialist medical care across orthopedics, trauma, sports medicine, neurosurgery, and general practice. The company delivers consultations, medical diagnosis, and both surgical and non-surgical treatments, with services that include joint replacement, spine care, foot and ankle procedures, minimally invasive orthopedic care, physiotherapy, and rehabilitation. It also offers health screening, mental health, and women’s health services, supporting a broader patient-care pathway within its clinics and medical centers. Basel Medical Group Ltd operates within the healthcare services market, where it serves patients seeking integrated treatment across multiple disciplines and procedures. Its current business model centers on clinical care delivery and specialist expertise in private healthcare settings in Singapore.
CEO Dr. Yen Feng Chhoa M.D. · 82 employees · Singapore · https://baselmedical.com